In Vitro efficacies and resistance profiles of rifampin-based combination regimens for biofilm-embedded methicillin-resistant Staphylococcus aureus

Hung Jen Tang, Chi Chung Chen, Kuo Chen Cheng, Kuan Ying Wu, Yi Chung Lin, Chun Cheng Zhang, Tzu Chieh Weng, Wen Liang Yu, Yu Hsin Chiu, Han Siong Toh, Shyh Ren Chiang, Bo An Su, Wen Chien Ko, Yin Ching Chuang

研究成果: 雜誌貢獻文章

32 引文 (Scopus)

摘要

To compare the in vitro antibacterial efficacies and resistance profiles of rifampin-based combinations against methicillin-resistant Staphylococcus aureus (MRSA) in a biofilm model, the antibacterial activities of vancomycin, teicoplanin, daptomycin, minocycline, linezolid, fusidic acid, fosfomycin, and tigecycline alone or in combination with rifampin against biofilm-embedded MRSA were measured. The rifampin-resistant mutation frequencies were evaluated. Of the rifampin-based combinations, rifampin enhances the antibacterial activities of and even synergizes with fusidic acid, tigecycline, and, to a lesser extent, linezolid, fosfomycin, and minocycline against biofilm-embedded MRSA. Such combinations with weaker rifampin resistance induction activities may provide a therapeutic advantage in MRSA biofilm-related infections.

原文英語
頁(從 - 到)5717-5720
頁數4
期刊Antimicrobial Agents and Chemotherapy
57
發行號11
DOIs
出版狀態已發佈 - 十一月 2013
對外發佈Yes

指紋

Rifampin
Methicillin-Resistant Staphylococcus aureus
Biofilms
Linezolid
Fusidic Acid
Fosfomycin
Minocycline
Daptomycin
Teicoplanin
Mutation Rate
Vancomycin
In Vitro Techniques
Infection

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Infectious Diseases

引用此文

In Vitro efficacies and resistance profiles of rifampin-based combination regimens for biofilm-embedded methicillin-resistant Staphylococcus aureus. / Tang, Hung Jen; Chen, Chi Chung; Cheng, Kuo Chen; Wu, Kuan Ying; Lin, Yi Chung; Zhang, Chun Cheng; Weng, Tzu Chieh; Yu, Wen Liang; Chiu, Yu Hsin; Toh, Han Siong; Chiang, Shyh Ren; Su, Bo An; Ko, Wen Chien; Chuang, Yin Ching.

於: Antimicrobial Agents and Chemotherapy, 卷 57, 編號 11, 11.2013, p. 5717-5720.

研究成果: 雜誌貢獻文章

Tang, HJ, Chen, CC, Cheng, KC, Wu, KY, Lin, YC, Zhang, CC, Weng, TC, Yu, WL, Chiu, YH, Toh, HS, Chiang, SR, Su, BA, Ko, WC & Chuang, YC 2013, 'In Vitro efficacies and resistance profiles of rifampin-based combination regimens for biofilm-embedded methicillin-resistant Staphylococcus aureus', Antimicrobial Agents and Chemotherapy, 卷 57, 編號 11, 頁 5717-5720. https://doi.org/10.1128/AAC.01236-13
Tang, Hung Jen ; Chen, Chi Chung ; Cheng, Kuo Chen ; Wu, Kuan Ying ; Lin, Yi Chung ; Zhang, Chun Cheng ; Weng, Tzu Chieh ; Yu, Wen Liang ; Chiu, Yu Hsin ; Toh, Han Siong ; Chiang, Shyh Ren ; Su, Bo An ; Ko, Wen Chien ; Chuang, Yin Ching. / In Vitro efficacies and resistance profiles of rifampin-based combination regimens for biofilm-embedded methicillin-resistant Staphylococcus aureus. 於: Antimicrobial Agents and Chemotherapy. 2013 ; 卷 57, 編號 11. 頁 5717-5720.
@article{178d19ba89ee4293a77701f295451068,
title = "In Vitro efficacies and resistance profiles of rifampin-based combination regimens for biofilm-embedded methicillin-resistant Staphylococcus aureus",
abstract = "To compare the in vitro antibacterial efficacies and resistance profiles of rifampin-based combinations against methicillin-resistant Staphylococcus aureus (MRSA) in a biofilm model, the antibacterial activities of vancomycin, teicoplanin, daptomycin, minocycline, linezolid, fusidic acid, fosfomycin, and tigecycline alone or in combination with rifampin against biofilm-embedded MRSA were measured. The rifampin-resistant mutation frequencies were evaluated. Of the rifampin-based combinations, rifampin enhances the antibacterial activities of and even synergizes with fusidic acid, tigecycline, and, to a lesser extent, linezolid, fosfomycin, and minocycline against biofilm-embedded MRSA. Such combinations with weaker rifampin resistance induction activities may provide a therapeutic advantage in MRSA biofilm-related infections.",
author = "Tang, {Hung Jen} and Chen, {Chi Chung} and Cheng, {Kuo Chen} and Wu, {Kuan Ying} and Lin, {Yi Chung} and Zhang, {Chun Cheng} and Weng, {Tzu Chieh} and Yu, {Wen Liang} and Chiu, {Yu Hsin} and Toh, {Han Siong} and Chiang, {Shyh Ren} and Su, {Bo An} and Ko, {Wen Chien} and Chuang, {Yin Ching}",
year = "2013",
month = "11",
doi = "10.1128/AAC.01236-13",
language = "English",
volume = "57",
pages = "5717--5720",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "11",

}

TY - JOUR

T1 - In Vitro efficacies and resistance profiles of rifampin-based combination regimens for biofilm-embedded methicillin-resistant Staphylococcus aureus

AU - Tang, Hung Jen

AU - Chen, Chi Chung

AU - Cheng, Kuo Chen

AU - Wu, Kuan Ying

AU - Lin, Yi Chung

AU - Zhang, Chun Cheng

AU - Weng, Tzu Chieh

AU - Yu, Wen Liang

AU - Chiu, Yu Hsin

AU - Toh, Han Siong

AU - Chiang, Shyh Ren

AU - Su, Bo An

AU - Ko, Wen Chien

AU - Chuang, Yin Ching

PY - 2013/11

Y1 - 2013/11

N2 - To compare the in vitro antibacterial efficacies and resistance profiles of rifampin-based combinations against methicillin-resistant Staphylococcus aureus (MRSA) in a biofilm model, the antibacterial activities of vancomycin, teicoplanin, daptomycin, minocycline, linezolid, fusidic acid, fosfomycin, and tigecycline alone or in combination with rifampin against biofilm-embedded MRSA were measured. The rifampin-resistant mutation frequencies were evaluated. Of the rifampin-based combinations, rifampin enhances the antibacterial activities of and even synergizes with fusidic acid, tigecycline, and, to a lesser extent, linezolid, fosfomycin, and minocycline against biofilm-embedded MRSA. Such combinations with weaker rifampin resistance induction activities may provide a therapeutic advantage in MRSA biofilm-related infections.

AB - To compare the in vitro antibacterial efficacies and resistance profiles of rifampin-based combinations against methicillin-resistant Staphylococcus aureus (MRSA) in a biofilm model, the antibacterial activities of vancomycin, teicoplanin, daptomycin, minocycline, linezolid, fusidic acid, fosfomycin, and tigecycline alone or in combination with rifampin against biofilm-embedded MRSA were measured. The rifampin-resistant mutation frequencies were evaluated. Of the rifampin-based combinations, rifampin enhances the antibacterial activities of and even synergizes with fusidic acid, tigecycline, and, to a lesser extent, linezolid, fosfomycin, and minocycline against biofilm-embedded MRSA. Such combinations with weaker rifampin resistance induction activities may provide a therapeutic advantage in MRSA biofilm-related infections.

UR - http://www.scopus.com/inward/record.url?scp=84885920711&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885920711&partnerID=8YFLogxK

U2 - 10.1128/AAC.01236-13

DO - 10.1128/AAC.01236-13

M3 - Article

C2 - 23959320

AN - SCOPUS:84885920711

VL - 57

SP - 5717

EP - 5720

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 11

ER -